danuglipron

Danuglipron is an oral, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Pfizer for the treatment of type 2 diabetes and obesity. It works by stimulating insulin secretion and inhibiting glucagon secretion to lower blood sugar levels, as well as delaying gastric emptying to regulate appetite and food intake, leading to weight loss. Danuglipron was designed as a non-peptide alternative to injectable GLP-1 agonists, with comparable efficacy in preclinical models. The most common adverse events reported were gastrointestinal in nature (nausea, diarrhea, vomiting). In April 2025, Pfizer discontinued development of danuglipron after a case of potential drug-induced liver injury was observed during clinical trials; the event resolved after discontinuation of the drug[1][2][3][4][6].

Other names

2230198-02-2Danuglipron [USAN]DN9IUI24GPDN-9IUI24GPDN 9IUI24GP